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The role of the promyelocytic leukemia (PML) protein has been widely tested in many dif-
ferent contexts, as attested by the hundreds of papers present in the literature. In most of
these studies, PML is regarded as a tumor suppressor, a notion on the whole accepted by
the scientific community. In this review, we examine how the concept of tumor-suppressor
gene has evolved until now and then systematically assess whether this assumption for
PML is supported by unambiguous experimental evidence.
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TUMOR SUPPRESSOR, AN EVOLVING CONCEPT
Despite more than 80 years of research on “characterizing prop-
erties,” the tumor-suppressor definition is still controversial. The
existence of chromosomal inherited traits that negatively regulate
tumor development was first postulated by Theodor Boveri (1),
who suggested the existence of inhibitory chromosomes that keep
cell proliferation in check and favor tumor development upon
removal. Formal proof for this concept came from cell fusion
experiments by Henry Harris, who showed that hybrids of normal
rodent cells and cancer cells exhibited growth properties similar
to normal cells (2).
Few years later, Alfred Knudson Jr. (3) proposed a genetic
mechanism for hereditary retinoblastoma (RB) that has influenced
cancer genetics until today. Knudson, on the basis of mathematical
and statistical analyses, hypothesized that the disease was caused by
two rate-limiting genetic lesions, one inherited and phenotypically
silent, and one acquired somatically during life. His theory was
then validated by cloning theRB gene, and it is commonly referred
to as the “two hit hypothesis.” In his model, Knudson introduced
a new class of cancer genes, the recessive anti-oncogenes, now
known as tumor-suppressor genes (TSGs) (4–6). Since then, the
two hit model has defined the experimental strategies for the iden-
tification of novel TSGs: (i) identification of genes involved in
cancer-predisposition, where the first “lesion” is inherited and the
second is acquired somatically; (ii) identification of genes inside
genomic regions displaying loss-of-heterozygosity (LOH) in can-
cer cells; (iii) identification of chromosomal regions from normal
cells that suppress the transformed phenotype. Those strategies
are embedded in the concept of double mutation, emphasizing
this aspect over gene function. For this reason many today con-
sider two inactivating hits in cancer to be the only acceptable proof
for the existence of a TSG.
In 1997, Haber and Harlow proposed a novel description of
TSGs as “genes that sustain loss-of-function mutations in the
development of cancer”(7), thus introducing a functional aspect in
the definition. The same year, Kinzler and Vogelstein distinguished
two functional classes of TSGs, namely, “gatekeepers” and “care-
takers” (8). Gatekeeper genes are designated to control cell-cycle
progression, e.g., adenomatous polyposis coli (APC), β-catenin
(CTNNB1), and RB, whereas caretaker genes maintain genome
integrity, e.g., breast cancer gene 1 (BRCA1), Bloom syndrome
gene (BLM ), and ataxia telangiectasia mutated gene (ATM ). Care-
taker mutations would lead to increased mutation rate, conse-
quently increasing the probability that gatekeepers become inac-
tivated. There are several studies on caretaker and gatekeeper
genes in the literature and the examples that follow below have
been intentionally chosen to reject the belief that two inactivating
mutations are required to define a tumor suppressor.
CDKN1B/p27KIP1 is a member of the cyclin-dependent kinase
inhibitor family and regulates cell-cycle progression. Two series of
evidence suggest that CDKN1B behaves as a classical TSG: LOH
at chromosome 12p13, encompassing the CDKN1B locus, is fre-
quently found in breast, prostate, and ovarian cancers (9–14), and
reduced CDKN1B protein is significantly associated with high-
grade and high-stage disease in those tumors [reviewed in (14)].
Reverse genetic experiments in mouse models, however, suggest a
different scenario: (i) Cdkn1b−/− and Cdkn1b± mice developed
intestinal and lung adenomas at higher frequency than wild type
mice, yet with similar latency and penetrance (15); (ii) tumors
fromCdkn1b±mice did not show mutations of the secondCdkn1b
allele; (iii) the CDKN1B protein was still expressed at about 50%
of the levels of wild type animals. In this case, as for other genes
likeDmtf1 (16, 17),Fhit (18, 19), andApc (20), to mention a few, it
is clear that the mutation of a single allele is sufficient to promote
tumorigenesis, a phenomenon that is called haplo-insufficiency.
Haplo-insufficient TSGs have been proposed to act by increasing
the population of mutated cells available for further mutations
[reviewed in (21)].
Haplo-insufficiency is not the only exception to the two hit
model. For example,ATM missense mutations are more common
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than ATM null mutations in breast cancers (22, 23), and mice car-
rying a copy of a mutated Atm allele develop more tumors than
mice heterozygous for a silenced Atm allele (Atm±) (24), suggest-
ing the existence of mono-allelic, dominant negative mutations
in tumor suppressors. Thus, in open contrast to the classical def-
inition of TSGs, dominant negative and haplo-insufficient genes
are able to give rise to tumors following a single mutation insult.
Finally, genetic mutations are not the only mechanism of func-
tional inactivation for TSGs. Analysis of CDKN2A (p16INK4) in
primary tumors, for example, revealed few inactivating muta-
tions, and CDKN2A CpG island hypermethylation in 20% of
cases (25), suggesting that epigenetic silencing of TSGs can drive
tumorigenesis as well.
Mounting evidence and exceptions to the two hit model sug-
gest that this definition of TSGs is too restrictive and in need of
revision. A TSG operative definition should probably focus more
on functional aspects, clear support from reverse genetic exper-
iments, and determination of gene/protein dosage for which the
two hit model is the extrema ratio. According to this view, we would
then define a TSG as a gene whose alteration is found in human
tumors, causes a reduction of its function, favors tumorigenesis
(as demonstrated by the introduction of the same modification
in animal experimental models), and if the overexpression of its
wild type form elicits anti-tumoral effects. Functional reduction
can be due to a reduced level of expression and to mutational
events, including dominant negative effects on the wild type allele.
With this paradigm in mind we questioned whether promyelocytic
leukemia (PML) fulfills all the above requirements to be considered
a true TSG.
PML EXPRESSION IN HUMAN TUMORS
The first criteria we have examined to assess if PML is a tumor
suppressor is the presence of genetic alterations or abnormal
expression in human cancers.
About 95% of human acute promyelocytic leukemia (APL)
cases harbor the oncogenic fusion gene PML-RARA as a result of
the translocation t(15;17), whose breakpoints are located within
the PML and the retinoic acid receptor α, RARA loci on chro-
mosome 15 and 17, respectively. In principle, PML function in
these cells is impaired by two concomitant events: PML haplo-
insufficiency, for the presence of a single WT PML autosome
and the expression of PML-RARA, which might interfere with
the function of the WT PML protein. PML is involved in the reg-
ulation of many cellular functions and some of them, such as the
activation of P53 by the DNA damage checkpoint response, rely
on its localization and organization in subnuclear structures called
PML-nuclear bodies (PML-NBs). PML-RARA functions as a dom-
inant negative factor in the process of PML-NB assembly, causing a
microspeckled distribution of PML. In this context, treatment with
retinoic acid and arsenic, two agents that induce disease-remission
in APL patients, leads to PML-RARA degradation, cell differen-
tiation, re-assembly of PML-NBs, and tumor regression. These
“therapeutic” effects establish a correlation between PML-NB
assembly and tumor suppression, yet formal evidence that PML-
NBs per se are responsible for tumor suppression is still missing.
Indeed, it cannot be excluded that APL regression is due, exclu-
sively, to other missing PML-RARA-associated functions after its
degradation. Notably, expression of X-RARA chimera, which does
not interfere with PML-NB assembly (P50-RARA, GCN4-RARA),
and where X represents a coiled-coil domain mediating RARA
homodimerization, maintains transforming potential, and reca-
pitulates the main biological properties of PML–RARA (26, 27).
However, the expression of X-RARA fusion proteins in mice, like
P50-RARA or GCN4-RARA, is not sufficient to drive tumorigen-
esis as PML-RARA or the CCPML-RARA protein, where the RARA
is fused to the coiled-coil region of PML, do (26). Pml−/− mice
expressing P50-Rara do not show increased incidence or accel-
eration of leukemia onset. This suggests that loss of Pml cannot
complement P50-Rara in restoring the leukemogenic potential to
a level comparable to that of PML-RARA, and that the PML-RARA
oncogene does not simply interfere with Pml and Rara functions
but has additional activities that cannot be recapitulated by sepa-
rating the two components in this way (27). In contrast with this
observation, Pml−/− Pml-Rara transgenic-mice show increased
incidence and acceleration of leukemia onset (28). Therefore is
not clear if PML-NBs really exert tumor suppressive functions
or not.
Immunohistochemical analysis of PML expression in human
tumors of different histologic origins shows that PML expression-
levels are reduced in a considerable number of cases, as compared
to the corresponding normal tissues. PML expression is absent in
49% of central nervous system (CNS) tumors (in 100% of medul-
loblastomas and over 90% of oligodendroglial tumors), 17% of
colon adenocarcinomas, 21% of lung tumors, 27% of prostate ade-
nocarcinomas, 31% of breast adenocarcinomas, 49% of germ cell
tumors, and 68% of non-Hodgkin’s lymphomas (in 83% of diffuse
large-cell lymphomas and 77% of follicular lymphomas) (29). In
addition, PML low-expression correlates with bad prognosis and
high-grade tumors for breast adenocarcinomas and prostate car-
cinomas (29). PML is phosphorylated by the extracellular signal-
regulated kinase ERK2 which facilitates the recruitment of the
peptidyl-prolyl cis/trans isomerase PIN1 and the following degra-
dation of PML by the proteasome (30, 31). Given the frequent
activation of ERK2 in several types of tumors, due to the sustained
action of paracrine growth factors or mutations, the ERK2/PML
axis may partly explain why PML expression is low in a consider-
able fraction of human tumors. However, mutational analysis of
the PML gene in 132 samples from different primary tumors and
human cell lines showed that PML is rarely mutated or subjected
to LOH mutations. Moreover, the fewPML mutations detected did
not correlate with PML protein-loss, suggesting that mutation is
not the main mechanism of PML inactivation in the tumor types
analyzed (29).
Triple negative breast cancer (TNBC) is a noticeable exception
to the common theme of PML loss in tumors. PML expression is
strongly associated with TNBC and basal high tumor-grade breast
cancers, which are among the most undifferentiated and untreat-
able breast cancers (32). Here, high levels of PML expression
correlate with early tumor recurrence, a signature of poor prog-
nosis, and mutations of the tumor-suppressor P53 (33). In vitro
experiments performed on MCF10A cells overexpressing PML
show increased survival to anoikis via the regulation of PPAR-α
and fatty acid oxidation, suggesting a crucial role for PML in the
regulation of cell metabolism (33).
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Chronic myeloid leukemia (CML) is also an exception. Indeed,
high levels of PML expression correlate with bad prognosis in
CML, and its function is critical to maintain leukemic initiating
cells (34). PML degradation induced by As2O3 (arsenic trioxide)
treatment allows exit from quiescence and exhaustion of cancer
stem cells (CSCs) in a murine model of the disease (34). This par-
allels the role of PML in hematopoietic stem cells (HSCs) where it
is highly expressed and controls HSC self-renewal and symmetric
division through its regulation of mTOR and PPAR-δ signaling
(fatty acid oxidation) (34). Additional proof of the general role
that PML plays in stem cell homeostasis comes from studies on
the nervous system. In mice PML expression is restricted to neural
progenitor cells (NPCs) in the developing neocortex where PML
regulates NPC proliferation and differentiation (35).
In summary, analysis of PML expression in human tumors
reveals two distinct situations: (i) reduced/loss-of expression in
different tumor types, most frequently in CNS tumors, which sug-
gests that PML may be a tumor suppressor; (ii) high expression
in CML and TNBC tumors, which, on the contrary, rely on PML
expression to, respectively, maintain unlimited self-renewal and
survive under metabolic stressing conditions. A controversial pic-
ture emerges from all these observations, indicating that the role
of PML in human malignancies is context dependent.
Pml LOSS IS NOT A GENERAL TUMOR-PROMOTING EVENT
Pml−/− mice are fertile, with birth rates in line with the expected
Mendelian frequency, and without gross phenotypic differences
compared to Pml± or Pml+/+ littermates (36). However, Pml−/−
mice are leukopenic, show an increased susceptibility to infec-
tions, a reduction of both granulocytes and monocytes, and have
an impaired capacity for terminal maturation of myeloid cells in
response to retinoic acid (36). Pml−/− mouse embryonic fibrob-
lasts (MEFs) show an increased rate of proliferation as compared to
Pml± or Pml+/+ MEFs without the hallmarks of transformation
(36). Notably, Pml−/− mice do not develop spontaneous tumors
at higher frequency than WT syngenic mice.
Experiments of cooperation between carcinogens/oncogenes
and the concomitant inactivation of Pml show a more compli-
cated picture. Cooperation between Pml-Rara and Pml inacti-
vation was assessed in a murine model of APL expressing the
Pml-Rara under the control of the human cathepsin G pro-
moter (28). In this case, the leukemia-free survival (LFS) of
hCG-Pml-Rara± Pml−/− and hCG-Pml-Rara± Pml± mice was sig-
nificantly reduced as compared to hCG-Pml-Rara± Pml+/+ mice
[mean LFS± SD, respectively: 434.4± 30.6 days (p< 0.0001),
498.9± 31.3 days (p= 0.003), 686.4± 35.5 days] showing a clear
acceleration of leukemia onset. Moreover, the incidence of
leukemia was significantly increased in Pml absence or haplo-
insufficiency (p< 0.001 for both) (28). However, these data were
not confirmed in a second independent model system where WT
and Pml−/− cells transduced with a retroviral vector expressing
Pml-Rara were compared for their ability to generate leukemia
upon transplantation into irradiated recipients. In contrast to the
previous study, leukemias developed significantly faster in a WT
background (p< 0.05) (37). Since the two experimental settings
were different it is difficult to draw a definitive conclusion about
the role of Pml in Pml-Rara – driven APL.
Pml cooperation has also been assessed in a murine model
of lung tumorigenesis driven by the oncogene K-RasG12D, which
induces non-small cell lung carcinomas (NSCLC) in mice (38).
In this model, Pml−/− mice showed an increased tumor burden
compared to Pml+/+ control animals, assessed as the number of
lung carcinomas/mouse after 8 weeks of continuous expression of
the K-RasG12D oncogene (p< 0.05) (39).
In a murine model of kidney tumor driven by the haplo-
insufficiency of the tuberous sclerosis protein 2 (TSC2), the pic-
ture, again, is different.Tsc2 heterozygosity leads to high MTORC1
activity, to the development of kidney cysts and,after a long latency,
to carcinomas (40, 41). Kidney tumor initiation, assessed by the
number of cysts and small carcinomas/kidney, is not affected in
Pml−/− Tsc2± mice. However, tumors from these mice were more
vascularized, showed higher proliferation and a more aggressive
histological profile (42) suggesting changes in tumor progression
rather than tumor initiation.
Pml−/−mice,challenged with 7,12-dimethylbenz(α)anthracene
(DMBA) and 12-O-tetradecanoylphorbol-13-acetate (TPA) two-
stage skin carcinogenesis, showed an increased number of papillo-
mas indicative of benign tumor initiation but only a mild increase
in the frequency of tumors undergoing malignant transforma-
tion (1.8 Pml+/+ vs. 2.3% Pml−/−) (36). Finally, Pml haplo-
insufficiency or complete inactivation does not affect frequency,
latency, and size of breast tumors in the MMTV/neu murine model
of mammary tumorigenesis (28).
Thus, deletion of Pml does not lead to transformation per se
but can favor tumorigenesis in some specific instances. Indeed, far
from providing a coherent and unifying picture for the role of PML
in tumorigenesis, these observations suggest that PML contribu-
tion depends on the specific background in which its inactivation
is achieved.
PML FUNCTIONS AND TUMOR SUPPRESSIVE PATHWAYS
Promyelocytic leukemia is a pleiotropic protein placed at the
crossroad of many regulatory pathways. DNA damage and repair,
anti-viral response, metabolic adaptation, induction of apopto-
sis/senescence, and telomere maintenance are some of the impor-
tant processes which regulate and are, in turn, regulated by PML.
Aim of this section is to examine the main tumor suppressive
pathways and factors that are engaged by PML.
PML, CELL DEATH, AND SENESCENCE
Promyelocytic leukemia modulates the activity and expression of
the known tumor-suppressor P53. Indeed, Pml−/− cells express
less P53 thanWT controls, both under steady-state conditions and
upon γ-irradiation (43, 44). PML interacts directly with the DNA
binding domain of the tumor-suppressor P53, colocalizes with
P53 in the PML-NBs and acts as a P53 transcriptional coactivator
(45–47). It activates P53 through multiple mechanisms: increasing
its acetylation and phosphorylation (44, 46, 48–50), binding and
inhibiting the main negative regulator of P53, the mouse double
minute 2 homolog, MDM2 (51–53), and promoting P53 deubiq-
uitination through the herpes-virus-associated ubiquitin-specific
protease, HAUSP (54, 55). In turn, activated P53 can directly
induce PML expression generating a positive feedback loop (56).
Biologically, the influence of PML on the P53 pathway may result
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in the regulation of stress-induced apoptosis or senescence on a
cell type-dependent basis. All these features are coherent with a
tumor suppressive role of PML exerted via P53.
Promyelocytic leukemia function in apoptosis is not limited
to the regulation of P53 or to the P53-dependent apoptotic path-
way. Indeed, both murine Pml−/− cells and PML siRNA interfered
human cells are defective for the induction of apoptosis triggered
by several factors, like type I and type II interferons (IFN), FAS,
tumor necrosis factor, ceramides, ionizing radiations (57, 58), and
transforming growth factor (TGF)-β, which induce apoptosis (59).
How can a single protein being involved in the regulation of
apoptosis from so many different stimuli? PML has been shown
to interact with the phosphatase PP2A and to modulate its activ-
ity on specific targets. Via PP2A PML can modify the sensitivity
to pro-survival and pro-apoptotic cues in at least two ways: (i)
recruiting PP2A phosphatase to nuclear PML-NBs, thereby de-
phosphorylating and inactivating AKT and its pro-survival func-
tions (60); (ii) recruiting PP2A to the inositol 1,4,5-trisphosphate
receptor, IP3R-3, to modulate Ca2+ release and storage at the
endosplasmic reticulum (ER). The physical structures where both
this regulation is achieved and cytoplasmic PML is localized
are called mitochondria-associated membranes (MAMs). Indeed,
sensitivity to apoptosis is dependent on the ability of cells to trans-
fer Ca2+ from the ER to the mitochondria. Ca2+ release, in turn,
induces mitochondrial Ca2+ loading, with a consequent release of
mitochondrial proteins involved in the apoptotic process, such as
cytochrome c, the apoptosis initiating factor AIF, and the complex
of second mitochondria-derived activator of caspases (SMAC)
with the direct IAP binding protein with low pI (DIABLO) (61, 62).
Conditions that reduce ER Ca2+ storage, and thus Ca2+ release
from the ER to the mitochondria, lower the probability of Ca2+
dependent apoptosis (62). In Pml−/− MEFs, both ER steady-state
(Ca2+) values and the increase of cytosolic Ca2+ concentration
after treatment with apoptotic stimuli like H2O2 are significantly
smaller than in Pml+/+ MEFs (63). PML appears to be essential
for PP2A tethering to the ER localized receptor IP3R-3, favoring
IP3R-3 dephosphorylation and Ca2+ storage. Conversely, IP3R-3
is hyper-phosphorylated in the absence of PML and this modifi-
cation decreases the Ca2+ release from the ER and the overload of
mitochondria increasing the apoptotic threshold (64).
The effect of PML overexpression is consistent with it hav-
ing a function in the regulation of survival, yet it is variable and
depends on cell-type and experimental conditions. Three kinds
of responses are observed upon PML overexpression: cell death
without the hallmarks of apoptosis, caspase3-dependent apop-
tosis, and senescence. PML overexpression leads to rapid cell
death without the typical features of apoptosis in immortalized
rat embryonic fibroblasts (65). Caspase-3 activity is not induced
upon overexpression of PML in these cells, implying that PML may
quickly trigger apoptosis with a caspases-3-independent mecha-
nism. Caspase-independent apoptosis is not unprecedented and
has been also observed after staurosporine treatment, serum depri-
vation, and overexpression of oncogenes like c-MYC or E1A (66).
Caspase-3-dependent apoptosis is triggered via P53 stabilization
and the regulation of mitochondrial Ca2+ overload as mentioned
above. Finally, introduction of PML into Pml−/− cells leads to
increased P53 levels, recruitment of P53 and its acetyltransferase
CREB binding protein (CBP) which mediates P53 stabilization to
PML-NBs, and cellular senescence (43, 44). PML is essential for
the induction of V-H-Ras-induced senescence via P53 acetylation
and activation (48). Interestingly, although all isoforms can bind
P53 and recruit it to PML-NBs, only the PML-IV isoform activates
P53 and triggers senescence even in the absence of PML-NBs (67).
Overexpression of PML-IV also induces senescence through
an RB-dependent mechanism (67, 68). Intriguingly, during the
induction of senescence, PML-NBs colocalize with RB, the E2F
transcription factor (69), and senescence-associated heterochro-
matin foci (SAHF), suggesting that heterochromatin proteins
(such as HIRA, HP1, and ASF1) transit via NBs before the estab-
lishment of heterochromatin foci and senescence (70, 71). PML
involvement in senescence induction has recently gained central
stage from studies on human ubiquitin ligase E6AP−/− B-cell lym-
phomas. E6AP is an E3 ubiquitin ligase shown to target PML
for degradation via the proteasome (72). E6AP−/− lymphomas
express elevated levels of PML and PML-NBs and show a par-
allel increase in markers of cellular senescence, including P21,
H3K9me3,and P16 (73). Equally, the expression of PML is restored
by down-regulation of E6AP in B-lymphoma cells, with concur-
rent induction of cellular senescence, suggesting that the overrid-
ing of PML-induced senescence is essential for B-cell lymphoma
progression (73).
PML AND CELL-CYCLE RESTRICTION
Promyelocytic leukemia function is also intertwined with a sec-
ond tumor suppressor called P21WAF1/CIP1. P21 belongs to the
cyclin-dependent kinase inhibitor family and its role in cell-cycle
restriction and differentiation has been widely investigated. PML
is required for the transactivation of the P21 promoter following
physiological doses of all-trans-retinoic acid (ATRA) treatment.
Concentrations of ATRA in the range of 10−7–10−6 M do not
activate the endogenous P21 gene in Pml−/− bone-marrow cells.
Since P21 up-regulation results in the terminal differentiation of
hematopoietic cells (74), the lack of P21 induction in Pml−/− cells
might contribute to the role of PML in controlling hematopoietic
myeloid differentiation (36). Terminal differentiation is indeed
a powerful tumor suppressive mechanism, which leads a cell to a
post-mitotic stage. Interestingly, PML-dependent accumulation of
P21 is both P53 dependent and independent. Indeed,PML knock-
down in P53−/− H1299 and HCT116 cells by siRNA interference
causes down-regulation of P21 expression, inhibition of the γ-
irradiation-induced up-regulation of P21, and decreased half-life
of the P21 protein (75). These data provide evidence for a P53-
independent functional relationship between PML and P21 in
γ-irradiation-induced DNA damage responses, and identify PML
as a positive post-translational regulator of P21 in P53−/− tumor
cells.
Two lines of evidence link PML and P21 activity in normal
and cancer cells. Interestingly, P21 and PML are important deter-
minants of HSC stemness, self-renewal, and quiescence (34, 76).
Experiments suggest that PML and P21 functions are important
to maintain self-renewal of CML stem cells and to sustain AML
leukemogenesis, respectively (77). In this context, PML and P21
both act as oncogenes rather than tumor suppressors. Notably,
stem cells may be endowed with unique checkpoint pathways, as
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compared to progenitors or more differentiated cells, suggesting
that cell-cycle restriction might increase their self-renewal poten-
tial (78). Importantly, P21 is also involved in DNA repair and it is
recruited to UV irradiation-induced DNA damage sites where it
interacts with proliferating cell nuclear antigen (PCNA), regulates
the interaction of repair factors with PCNA, and protects PCNA
from degradation (79).
Previous studies also indicated that PML post-transcriptionally
represses several genes involved in growth promotion and cell-
cycle progression, including cyclins (D1, E1, A2, B1) and c-MYC
(43, 80–82). In addition, PML can influence entry into the cell
cycle by regulating the activation of the tumor-suppressor RB.
Interestingly, PML binds to the phosphatase PP1, and promotes
PP1-dependent dephosphorylation of RB in neural stem cells (35).
In PML−/− mice, the amount of phosphorylated RB in NPCs
is increased and correlates with higher proliferation and defec-
tive exit from the cell cycle without any substantial effect on
apoptosis (35).
PML AND DNA REPAIR
An important role for PML in the response to DNA damage and
repair is also suggested by the dynamic localization of several play-
ers of the DNA damage detection and repair machinery, such as
the Bloom syndrome protein (BLM) and others like the ataxia
telangiectasia and Rad3 related protein (ATR), the cds1 homolog
kinase 2 (CHK2), and the Nijmegen Breakage Syndrome 1 (NBS1),
to PML-NBs [reviewed in (52)]. Indeed, Pml−/− MEFs show a
greatly augmented frequency of sister chromatid exchange (SCE)
which is a distinctive molecular feature of Bloom syndrome cell
genomic instability, suggesting that the localization of BLM to
PML-NB is important to ensure BLM proper function (83). Thus,
PML expression is a barrier to genomic instability, contributing
to restrain the effects of DNA damage and oncogenic mutations.
On the other hand, DNA repair systems are also potentially harm-
ful for the organism, particularly in cells with a chronic source of
DNA damage like cancer cells.
PML AND VIRAL INFECTION
Promyelocytic leukemia confers resistance on RNA viruses by
interacting with viral proteins and inhibiting their functions or,
in a P53-dependent way, by inducing apoptosis of infected cells
(84). In this way, PML expression restrains the propagation of
infection and reduces the chance of possible oncogenic mutations
due to viral DNA integration into the cell genome. The IFN is
the best characterized inducer of PML, and all IFNs (α, β, and γ)
sharply enhance mRNA and protein levels of PML, leading to a
marked increase in the number and size of PML-NBs (85). Most
of the studies implicating PML in anti-viral defense have been
performed with the isoforms PML III, IV, or VI, whereas those
implicating PML in apoptosis and senescence were performed with
PML-IV isoform.
PML AND ANGIOGENESIS
Promyelocytic leukemia affects angiogenesis by negatively regu-
lating the Akt-mTOR pathway which controls the synthesis of
the hypoxia inducible factor HIF-1α, the main factor regulat-
ing cell response to hypoxia (86). Therefore, PML loss not only
decreases PML tumor suppressive functions but also amplifies
tumor hypoxia responses, such as angiogenesis, migration, meta-
bolic reprograming, epithelial-to-mesenchymal transition, tumor
growth, and chemoresistance, and these functions collectively gen-
erate very aggressive tumors. The HIF-1α high, Kelch-like protein
KLHL20 high (PML E3 ubiquitin ligase), the peptidyl-prolyl cis-
trans isomerase NIMA-interacting Pin1 high and the resulting
PML low-expression profile correlate with high-grade tumors
(87). PML deficiency, indeed, leads to increased neoangiogen-
esis and elevated expression of pro-angiogenic factors such as
the vascular endothelial growth factor (VEGF) in human and
mouse tumors, thus supporting growth and spreading of the
disease (86).
PML AND TELOMERE MAINTENANCE
Promyelocytic leukemia is also involved in a mechanism of telom-
ere maintenance known as alternative lengthening of telomeres
(ALT). ALT occurs in telomerase-negative cell lines and PML forms
ALT associated PML bodies (APBs) (88, 89). The appearance of
APBs correlates with the stabilization of telomere length in ALT cell
lines, suggesting that these bodies are responsible for the preserva-
tion of telomere length in the absence of telomerase activity (88,
89). The involvement of PML as a positive regulator of telomere
maintenance on one hand suggests that its function may prevent
genomic instability, on the other, it may grant telomerase-negative
cancer cells a way to overcome replicative senescence.
PML AND AUTOPHAGY
Autophagy is a catabolic process that allows lysosomal-mediated
degradation of unnecessary or dysfunctional cellular compo-
nents. Autophagy functions as an adaptive mechanism, which
grants cell survival under several stress conditions (e.g., star-
vation, hypoxia) and maintains cellular integrity by clearing of
subcellular debris and regeneration of metabolic precursors (90–
93). In cells growing in a nutrient-rich environment (94, 95)
autophagy is negatively regulated by mTOR and AKT signaling,
two factors that are often constitutively active in AML (96). In
line with these observations, mice lacking the autophagy-related
protein 7 (Atg7) in HSCs develop an atypical myeloprolifera-
tive disorder, reminiscent of myelodisplastic syndrome (MDS),
which progresses to AML (97). PML inhibits the AKT-mTOR
signaling pathway, thus suggesting an involvement in the reg-
ulation of autophagy. A study from Laane and colleagues (98)
shows that impairment of autophagy by siRNA-mediated repres-
sion of the autophagy regulator BECN1 interferes with gluco-
corticoid dexamethasone-mediated lymphoblastic leukemia cell
death. Dexamethasone treatment leads to PML up-regulation, its
interaction with AKT, and PML-dependent AKT dephosphory-
lation, which was required for dexamethasone-dependent cyto-
toxicity effects on thymocytes. Conversely, autophagy was shown
to contribute to ATRA mediated differentiation and PML-RARA
degradation in NB4 cells, where PML-RARA is targeted to lyso-
somes by the ubiquitin binding adaptor protein p62/SQSTM1
(99, 100). These studies coherently associate PML activity with
autophagy induction and tumor suppression in acute promyelo-
cytic leukemia. However, the role of autophagy in tumorigenesis
and tumor maintenance is still controversial.
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In conclusion, PML functions are complex, and a comprehen-
sive model which clearly summarizes how they are interlinked is
still missing. Definitely, PML mediates apoptosis and senescence,
two very important strategies for limiting tumor development and
progression. However, some of PML activities, such as its control
of cell-cycle progression via P21 and RB or its role in telomere
maintenance, hide an oncogenic potential that some tumors might
exploit to survive. Thus, PML functions cannot be considered
univocally tumor suppressive.
DISCUSSION
Promyelocytic leukemia has an important role in the regulation
of stress response in normal cells. Its complex regulatory network
allows integration of signals coming from several pathways. As a
consequence, PML seems to be a key factor in cell fate decisions,
i.e., self-renewal vs. differentiation, adaptation vs. apoptosis or
senescence. In vitro, PML activity is necessary for the induction of
apoptosis in response to many different stimuli, and overexpres-
sion of PML leads to apoptosis or senescence, as demonstrated
from both in vitro experiments and in vivo observations. Despite
this centrality in mediating apoptosis or cell-cycle arrest, PML
inactivation is not sufficient to increase the rate of spontaneous
cancers in mice. However, in murine experimental models of
cancer, PML loss can cooperate with some oncogenic lesions to
increase tumor initiation and progression.
Altogether, the emerging picture is that of a context-dependent
contribution of PML to both tumorigenesis and tumor suppres-
sion, and it is not possible to conclude which way the balance tilts
(Figure 1).
Non-small cell lung carcinoma tumorigenesis driven by the
oncogene K-RasG12D, for example, benefits from PML loss, which
leads to an increased number of lung adenocarcinomas. However,
Pml−/− mice treated with the DMBA-TPA protocol, while show-
ing increased papilloma incidence, develop few more malignant
tumors, and Tsc2± and MMTV neu driven kidney and mammary
tumors, respectively, do not show differences in tumor initiation.
Moreover, PML expression is required to maintain self-renewal
and avoid cell death by anoikis in CML and TNBC, respectively,
suggesting that some tumors may even rely on PML expression to
sustain the malignant phenotype. Hence, the simple notion that
PML is a general tumor suppressor that serves as a strong pro-
apoptotic and pro-senescence determinant is not supported by
the available data. Which of the multiple functions of PML is cru-
cial or contrasts cancer development and maintenance depends
probably on the specific physiological state of each neoplasia,
and it is determined by the mutations occurring in that spe-
cific cell. Consistent with this hypothesis is the observation that
PML expression correlates with high frequency of mutated P53 in
TNBC. It is tempting to speculate that also the reciprocal may be
true, so that reduced PML expression could affect tumors where
the P53 or RB pathways are not inactivated. Furthermore, PML
loss of expression in human tumors, which is mostly regulated
at the level of protein stability, may be the result of the constitu-
tive activation of common growth factor cues, which impinge into
the same ERK2/PIN1/KLHL20/PML axis leading to PML protein
degradation.
In recent years supporting evidence for the CSC or hierarchi-
cal model has been collected, shedding light on the crucial role of
CSCs in tumor maintenance. The emerging concept that CSCs
are the real biological reservoir of malignancies and that it is
possible to exhaust CSC self-renewal by driving CSCs out of quies-
cence is a powerful paradigm which has just begun to be exploited
FIGURE 1 | Key results sustaining a role for PML as a tumor suppressor (green box), oncogene (red box), or in contrast with the hypothesis that PML
is a tumor suppressor (yellow box).
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experimentally and in clinical trials. Proof of concept experiments
on this issue have been performed in murine models of CML (34)
and AML (77). In this regard, PML is an interesting potential target
since it is highly expressed in stem cells, restrains cell-cycle pro-
gression and maintains stem cell self-renewal [reviewed in (101)].
Future experiments should probably reassess the expression
level of PML more specifically in the CSC compartment of human
tumors. It is indeed possible that PML expression is confined to
the CSCs and absent in the more differentiated cancer progenitors.
Since CSCs very often constitute only a minor fraction of the whole
tumor population, PML expression may have gone unnoticed in
previous analyses, underestimating the importance of PML in the
maintenance of a specific tumor.
If this is the case, PML function in support of self-renewal may
be more important than its tumor-suppressor activities and the
applicability of well-established therapeutic agents, like As2O3,
which lead to PML degradation may be much broader than
expected.
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